The BLOC1S5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human A-549 lung adenocarcinoma cell line, designed to disrupt expression of the BLOC1S5 gene. This heterogeneous population carries diverse BLOC1S5 mutations, enabling robust functional studies without clonal artifacts. As a core subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1), BLOC1S5 is critical for endosomal sorting, making these cells a valuable resource for probing lysosome-related organelle biogenesis and Hermansky-Pudlak syndrome (HPS) pathogenesis.
The parental A-549 cell line is a well-characterized model for non-small cell lung cancer (NSCLC), originally established from a lung adenocarcinoma in a 58-year-old male. These cells display type II alveolar epithelial characteristics and harbor a KRAS G12S oncogenic mutation while maintaining wild-type TP53. A-549 cells are extensively used in cancer biology, drug discovery, and intracellular trafficking investigations due to their rapid proliferation, defined signaling networks, and amenability to imaging and functional assays.
BLOC1S5 encodes a scaffold subunit of BLOC-1, a multi-protein complex that sorts cargo at early endosomes for delivery to lysosome-related organelles such as melanosomes and platelet dense granules. BLOC-1 cooperates with AP-3, BLOC-2, and Rab32/Rab38 GTPases to direct trafficking of melanosomal enzymes (e.g., TYRP1) and dense granule contents (e.g., serotonin, ADP). BLOC1S5 interacts with other BLOC-1 subunits (BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S4, DTNBP1, BLOC1S6, SNAPIN) and is transcriptionally regulated by MITF and TFEB. Disruption of BLOC1S5 abrogates BLOC-1 assembly, impairing downstream delivery to VAMP7- and syntaxin 13-positive compartments, thereby recapitulating Hermansky-Pudlak syndrome trafficking defects.
In the A-549 background, BLOC1S5 knockout allows dissection of how BLOC-1-dependent endosomal sorting intersects with oncogenic KRAS signaling and lung tumor cell physiology. A-549 cells possess active endocytic pathways, making them suitable for studying the impact of BLOC-1 loss on receptor recycling, lysosomal pH regulation, and vesicle secretion. Given that HPS patients often develop pulmonary fibrosis, this model provides a platform to investigate epithelial?Cmesenchymal transition and fibrotic mechanisms in alveolar epithelial cells, bridging rare genetic disorders and common lung pathologies.
These polyclonal knockout cells are applicable to a wide range of assays. Western blotting verifies BLOC1S5 depletion and destabilization of partner subunits. Immunofluorescence using markers like TYRP1 and LAMP1 reveals mislocalization of melanosomal proteins and lysosomal abnormalities. Functional assays, including transferrin recycling kinetics, lysosomal pH measurements, and platelet dense granule ATP secretion (upon co-culture with megakaryocytes), quantify trafficking deficits. Electron microscopy visualizes aberrant melanosome morphology. These tools support HPS disease modeling, intracellular trafficking research, platelet biology studies, and lung adenocarcinoma investigations. For further information, please contact Ascent Research.
